Preformulation studies on the development of a transdermal therapeutic system with captopril

Authors

DOI:

https://doi.org/10.15587/2519-4852.2026.353006

Keywords:

hypertension, captopril, in vitro permeability, transdermal therapeutic system (TTS)

Abstract

The article presents the results of a study of the process of captopril penetration through a semipermeable membrane by in vitro dialysis to practically confirm the possibility of its use for creating new forms of delivery – transdermal therapeutic systems (TTS).

The aim: Preformulation studies of pharmaceutical development of a transdermal dosage form of TTS with antihypertensive action with captopril, determination of the nature and kinetic parameters of the process of captopril permeability through a semipermeable membrane in vitro, as well as the influence of the initial concentration of the selected active pharmaceutical ingredient (API) on this process.

Materials and methods: At the initial stage of development of antihypertensive TTS, the in vitro process of captopril permeability through a semi-permeable membrane by dialysis was investigated at (37±0.5) °C. A phosphate buffer solution (pH 7.4) was used as a diffusion medium. The initial concentration of captopril in the donor solution was 30 mg/ml.

Results: Based on the analysis of the obtained experimental values of the amount of the studied substance in the sample of dialysate Хi and the specific flux gradient per unit of time ΔQt it was noted that the process of captopril permeability in model conditions is characterized by a uniform rate and corresponds to zero-order kinetics. The high value of the correlation coefficient R = 0.9996 for the obtained kinetic equation confirms the linear dependence of passage through the membrane of the studied substance on time.

Conclusion: Studies conducted to determine quantitative permeability characteristics have shown, first, the ability of molecules of the selected substances to overcome membrane barriers and allow a positive assessment of the acceptability of this active pharmaceutical ingredient as attractive for the creation of TTS

Supporting Agency

  • Ministry of Health of Ukraine from the state budget according to the topic «Preformulation studies of biopharmaceutical properties of active pharmaceutical ingredients with antihypertensive action for the creation of innovative transdermal drug delivery systems» (state registration number: 0122U001605).

Author Biographies

Tatyana Shyteyeva, National University of Pharmacy

PhD, Leading Researcher

State Research Laboratory for Quality Control of Medicinal Products

Elena Bezchasnyuk, National University of Pharmacy

PhD, Associate Professor

State Research Laboratory for Quality Control of Medicinal Products

Oleg Kryskiv, National University of Pharmacy

PhD, Associate Professor

Department of General Chemistry

References

  1. Mills, K. T., Stefanescu, A., He, J. (2020). The global epidemiology of hypertension. Nature Reviews Nephrology, 16 (4), 223–237. https://doi.org/10.1038/s41581-019-0244-2
  2. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C. et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71 (6), 1269–1324. https://doi.org/10.1161/hyp.0000000000000066
  3. Hypertension. World Health Organization. Available at: https://www.who.int/health-topics/hypertension/#tab=tab_1
  4. World Hypertension Day 2023. International Society of Hypertension. Available at: https://ish-world.com/world-hypertension-day-2023/
  5. Unger, T., Borghi, C., Charchar, F., Khan, N. A., Poulter, N. R., Prabhakaran, D. et al. (2020). 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension, 75 (6), 1334–1357. https://doi.org/10.1161/hypertensionaha.120.15026
  6. Herman, L. L., Padala, S. A., Ahmed, I., Bashir, K. (2023). Angiotensin-Converting Enzyme Inhibitors (ACEI). StatPearls. StatPearls Publishing. Available at: https://pubmed.ncbi.nlm.nih.gov/28613705/
  7. Chen, Y. J., Li, L. J., Tang, W. L., Song, J. Y., Qiu, R., Li, Q. et al. (2018). First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension. Cochrane Database of Systematic Reviews, 2018 (11). https://doi.org/10.1002/14651858.cd008170.pub3
  8. Marte, F., Sankar, P., Patel, P., Cassagnol, M. (2024). Captopril. StatPearls. StatPearls Publishing. Available at: https://www.ncbi.nlm.nih.gov/books/NBK535386/
  9. Obied, A. H. H., Ahmed, A. A. E. (2021). Evaluation of the clinical outcome of captopril use for hypertensive urgency in Khartoum State’s emergency centres. African Journal of Emergency Medicine, 11 (1), 202–206. https://doi.org/10.1016/j.afjem.2020.10.003
  10. Captopril (Captoprilum). Compendium. Available at: https://compendium.com.ua/akt/67/3102/captoprilum/
  11. Shyteyeva, T., Bezchasnyuk, E., Kryskiv, O., Grynenko, V. (2023). Substantiation of creation of transdermal forms of drug delivery with antihypertensive action. ScienceRise: Pharmaceutical Science, 4 (44), 104–113. https://doi.org/10.15587/2519-4852.2023.286303
  12. Pastore, M. N., Kalia, Y. N., Horstmann, M., Roberts, M. S. (2015). Transdermal patches: history, development and pharmacology. British Journal of Pharmacology, 172 (9), 2179–2209. https://doi.org/10.1111/bph.13059
  13. Patches, transdermal. (2016) Ph. Eur. 10.0. Strasbourg: Council of Europe, 925. Available at: https://www.scribd.com/document/508063535/European-Pharmacopoeia-10-0#page=957
  14. Vachhal, I. K., Kumar, K., Joshi, A., Rajput, V. (2023). Transdermal patches: updated review as a novel drug delivery system. UPI Journal of Pharmaceutical, Medical and Health Sciences, 6 (4), 7–11. https://doi.org/10.37022/jpmhs.v6i4.95
  15. Xu, F., Qiu, Z., Zhang, M., Ren, Y., Kong, L., Liu, Y. et al. (2025). Transdermal Drug Delivery Systems: A Comprehensive Review of Mechanisms, Technologies, and Clinical Applications. Pharmaceutical Research, 42 (12), 2429–2442. https://doi.org/10.1007/s11095-025-03962-9
  16. Crasta, A., Painginkar, T., Sreedevi, A., Pawar, S. D., Badamane Sathyanarayana, M. et al. (2025). Transdermal drug delivery system: A comprehensive review of innovative strategies, applications, and regulatory perspectives. OpenNano, 24, 100245. https://doi.org/10.1016/j.onano.2025.100245
  17. Lee, H., Song, C., Baik, S., Kim, D., Hyeon, T., Kim, D.-H. (2018). Device-assisted transdermal drug delivery. Advanced Drug Delivery Reviews, 127, 35–45. https://doi.org/10.1016/j.addr.2017.08.009
  18. Global Transdermal Drug Delivery Market Trends and Drivers, Restraints, and Opportunities 2017–2023 (2018). Dublin. PRNewswire. Available at: https://www.prnewswire.com/news-releases/global-transdermal-drug-delivery-market-2017-2023-key-players-are-3m-boehringer-ingelheim-johnson-and-johnson-mylan-nv-novartis-and-glaxosmithkline-300591034.html
  19. Ramadon, D., McCrudden, M. T. C., Courtenay, A. J., Donnelly, R. F. (2021). Enhancement strategies for transdermal drug delivery systems: current trends and applications. Drug Delivery and Translational Research, 12 (4), 758–791. https://doi.org/10.1007/s13346-021-00909-6
  20. Uttekar, P., Kulkarni, A., Chaudhari, P., Dhage, M., Dhangarmali, V. (2016). Formulation and evaluation of captopril transdermal patches for the treatment of hypertension. Der Pharmacia Lettre, 8 (5). 12–16. Available at: https://www.scholarsresearchlibrary.com/articles/formulation-and-evaluation-of-captopril-transdermal-patches-for-thetreatment-of-hypertension.pdf
  21. Debasmita, G., Bhowmick, M., Bhowmick, P. (2023). Fabrication and characterization of ace inhibitor loaded transdermal patches. International Journal of Allied Medical Sciences and Clinical Research, 11 (2), 152–161.
  22. Ramadon, D., Muliawardani, F., Nisrina, N. A., Tri Hamda, O., Iswandana, R., Wahyuni, T. et al. (2024). Transdermal delivery of captopril using poly(vinyl pyrrolidone)/poly(vinyl alcohol)-based dissolving and hydrogel-forming microneedles: A proof of concept. European Polymer Journal, 208, 112860. https://doi.org/10.1016/j.eurpolymj.2024.112860
  23. Shyteyeva, T., Bezchasnyuk, E., Kryskiv, O. (2022) In vitro Study of the Permeability of Enalapril Maleate through a Semipermeable Membrane in the Process of Pharmaceutical Development of a Transdermal Therapeutic System. Pharmakeftiki, 34 (4), 166–173. Available at: https://pharmakeftiki.hsmc.gr/pj/issue/view/22/22
  24. Shyteyeva, T., Bezchasnyuk, E., Kryskiv, O., Baranova, I. (2024). Biopharmaceutical aspects of the development of transdermal forms of Lisinopril dihydrate. Current Issues in Pharmacy and Medical Sciences, 37 (3), 166–170. https://doi.org/10.2478/cipms-2024-0027
  25. Babiker, M. E., Farah, H. F., Heyam, S. A. (2021) Captopril: An Overview of Discovery, Develop and Post-marketing Surveillan ceasan Effective Anti-hypertensive Drug. Acta Scientific Pharmaceutical Sciences, 5 (4). 6–9. Available at: https://actascientific.com/ASPS/ASPS-05-0695.php
  26. Chien, Y. W. (1987). Development of Transdermal Drug Delivery Systems. Drug Development and Industrial Pharmacy, 13 (4-5), 589–651. https://doi.org/10.3109/03639048709105212
  27. Kaptopryl (2014) Derzhavna farmakopeia Ukrainy. Vol. 2. Kharkiv: Derzhavne pidpryiemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv», 347–350.
  28. Captopril (Captoprilum) (2016). The International Pharmacopoeia. Available at: https://cdn.who.int/media/docs/default-source/medicines/pharmacopoeia/omitted-monographs/captopril.pdf?sfvrsn=7d2ac6d4_5
  29. 3.N.1. Statystychnyi analiz rezultativ khimichnoho eksperymentu (2023) Derzhavna farmakopeia Ukrainy (druhe vydannia). Dopovnennia 6. Kharkiv: Derzhavne pidpryiemstvo «Ukrainskyi naukovyi farmakopeinyi tsentr yakosti likarskykh zasobiv», 30–40.
  30. 9.6. Uniformity of content of single-dose preparations (2016) Ph. Eur. 10.0. Strasbourg, France: Council of Europe, 336. Available at: https://www.scribd.com/document/508063535/European-Pharmacopoeia-10-0#page=368
Preformulation studies on the development of a transdermal therapeutic system with captopril

Downloads

Published

2026-02-28

How to Cite

Shyteyeva, T., Bezchasnyuk, E., & Kryskiv, O. (2026). Preformulation studies on the development of a transdermal therapeutic system with captopril. ScienceRise: Pharmaceutical Science, (1 (59), 63–68. https://doi.org/10.15587/2519-4852.2026.353006

Issue

No. 1 (59) (2026)

Section

Pharmaceutical Science

License

Copyright (c) 2026 Tatyana Shyteyeva, Elena Bezchasnyuk, Oleg Kryskiv

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.